SB 1528
Plain-language analysis
Generated analysis, not an official summary or legal advice. Confirm with linked Oregon documents.
The measure expands Oregon’s prescription drug price transparency framework by requiring manufacturers to annually report comprehensive data on all patient assistance programs (PAPs) serving Oregon residents, regardless of whether the associated drugs triggered standard price-increase reporting thresholds. This creates a state-maintained public database of manufacturer financial aid metrics that will inform legislative recommendations to contain drug costs and reduce consumer out-of-pocket burdens.
Basis: Inferred · Sources: Senate Amendments to Introduced; Staff Measure Summary A
The measure responds to a specific recommendation in the 2025 legislative report from Oregon’s Prescription Drug Price Transparency program, which advised requiring manufacturers to report annually on all patient assistance programs they maintain or fund.
Basis: Official analysis · Source: Staff Measure Summary A
Inferred from cited text; not a stated purpose.
The amendment removes the prior limitation tying PAP reporting only to drugs that triggered price-increase thresholds, suggesting a legislative intent to capture the full scope of manufacturer-sponsored financial aid programs that may offset high drug prices and obscure true net costs.
Basis: Inferred · Sources: Senate Amendments to Introduced; A-Engrossed
Must collect and report granular PAP data annually by March 15, including participation counts, total discount values, refill eligibility, program duration, and verification criteria. Civil penalties apply for late, missing, inaccurate, or unresponsive reporting.
Basis: Inferred · Source: Senate Amendments to Introduced
Gain access to a public state database detailing manufacturer financial assistance programs, potentially improving transparency about out-of-pocket cost reductions, program expiration dates, and eligibility hurdles.
Basis: Inferred · Source: Senate Amendments to Introduced
Bears administrative responsibility to receive reports, verify data, manage trade secret exemptions, publish information online, and compile annual legislative recommendations.
Basis: Inferred · Source: Senate Amendments to Introduced
Receive expanded pricing and PAP data to inform future policy recommendations on drug affordability, commercial insurance premiums, and public program costs.
Basis: Inferred · Source: Senate Amendments to Introduced
Manufacturers face new compliance costs for data aggregation across all PAPs, even those not tied to price-increase triggers. DCBS incurs minimal fiscal impact per official analysis but must allocate staff for verification and publication.
Basis: Inferred · Sources: Fiscal Impact Statement A; IS_Impact SB 1528 2
Public website publication of PAP metrics may alter consumer behavior by revealing program limitations, while manufacturers may face reputational or market pressure if data shows limited assistance or high profit margins relative to costs.
Basis: Inferred · Source: Senate Amendments to Introduced
DCBS gains authority to request additional documentation and set response timelines by rule, with civil penalties enforceable under existing statute for noncompliance.
Basis: Inferred · Source: Senate Amendments to Introduced
Low-income patients on high-cost specialty drugs
Reported PAP data demonstrates that manufacturer assistance effectively caps out-of-pocket costs at $0 for eligible enrollees, prompting legislative action to expand state-subsidized coverage and align public programs with manufacturer aid thresholds.
Basis: Inferred · Source: Senate Amendments to Introduced
Manufacturers with complex PAP structures
A manufacturer faces severe civil penalties and public disclosure of trade-secret pricing methodologies after failing to meet DCBS documentation requests, forcing the company to withdraw the program from Oregon entirely and leaving patients with unaffordable full-price drugs.
Basis: Inferred · Source: Senate Amendments to Introduced
inference
Sources · Senate Amendments to Introduced
Expanding PAP reporting captures comprehensive financial aid data to inform affordability policy but imposes compliance burdens on manufacturers and risks reduced transparency if trade secret exemptions are broadly applied.
Granular visibility into patient assistance programs enables targeted legislative cost-containment tools.
Basis: Inferred · Source: Staff Measure Summary A
Public data disclosure may pressure manufacturers to align assistance programs with consumer needs and reduce opaque pricing practices.
Basis: Inferred · Source: Senate Amendments to Introduced
Administrative and data-aggregation costs for DCBS and manufacturers, despite minimal direct fiscal impact.
Basis: Inferred · Source: Fiscal Impact Statement A
Manufacturers may restrict or withdraw PAPs from Oregon if compliance complexity or privacy concerns outweigh program viability.
Basis: Inferred · Source: Senate Amendments to Introduced
The Senate Amendment replaces the prior version and modifies subsection (5) by removing the limitation that tied PAP reporting only to drugs triggering price-increase thresholds. The current text requires manufacturers to report on all patient assistance programs offered or funded by the manufacturer that provided assistance to Oregon consumers during the previous calendar year, regardless of drug pricing triggers.
Expanded reporting scope from price-triggered drugs to all PAPs serving Oregon residents.
Captures comprehensive financial aid data that may offset high drug prices and informs broader affordability policy.
Sources · Senate Amendments to Introduced; A-Engrossed
Tradeoff: Broader transparency and policy utility versus increased manufacturer compliance burden and potential program withdrawal risk.
high confidence. Analysis is grounded in official legislative revenue, fiscal, and staff analysis documents alongside the exact published bill text. No external speculation or unverified claims are included.
Possible effects if adopted; not current bill text.
If adopted, this amendment would replace the original study-focused bill with substantive Medicaid drug purchasing reforms. It would legally mandate the Oregon Health Authority (OHA) to secure the lowest net cost for prescription drugs across all medical assistance programs, establish a new advisory cooperative, authorize OHA to use a third-party purchasing agent, expand OHA’s authority to negotiate supplemental rebates and join multistate purchasing pools, and delay certain existing statutory effective dates. Material consequences include centralized procurement authority, potential shifts in formulary access and out-of-pocket costs for medical assistance recipients, new annual reporting obligations, and altered negotiation dynamics with pharmaceutical manufacturers.
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Official sources do not state why this measure was proposed.
Sponsor testimony, staff summaries, committee materials, or statutory findings may explain it.
Inferred from cited text; not a stated purpose.
The amendment likely aims to implement a specific recommendation from Oregon’s Prescription Drug Price Transparency program to centralize Medicaid drug purchasing and leverage bulk negotiation for cost savings.
Basis: Inferred · Source: Staff Measure Summary A
Gains statutory mandate to negotiate supplemental rebates, contract with a third-party purchasing agent, appoint cooperative members, and submit annual reports on drug costs and preferred drug list alignment.
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Subject to OHA’s centralized drug pricing and formulary alignment; may experience altered out-of-pocket costs, changed formulary access, or premium impacts depending on negotiated rebate outcomes.
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Included in the lowest-cost purchasing mandate, potentially altering their drug coverage terms and procurement pathways.
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Face new statutory obligation to negotiate supplemental rebates with OHA and potentially multistate pools beyond federal requirements.
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Appointed volunteers tasked with advising on drug pricing, rebate leverage, and formulary alignment, serving at the pleasure of the OHA Director without compensation.
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
OHA must appoint cooperative members by January 1, 2027, implement lowest-cost purchasing steps by January 1, 2028, and submit annual reports on rebates, savings, and preferred drug list alignment. Manufacturers must engage in supplemental rebate negotiations.
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Shifts procurement risk to OHA; may reduce state drug expenditures but requires administrative infrastructure for the cooperative and purchasing agent. Formulary changes could alter eligibility or access pathways for specific drugs.
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Annual reporting creates transparency, while executive session provisions allow confidential commercial discussions, potentially limiting public scrutiny of specific contract terms.
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
State Budget and Medical Assistance Recipients
OHA successfully leverages multistate pooling and supplemental rebates to reduce Medicaid drug expenditures by 15–20%, significantly lowering state budget pressure and stabilizing CCO premiums for medical assistance recipients.
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Providers and Recipients of Specialized Medications
The third-party purchasing agent fails to secure competitive rates, or the cooperative’s advisory role creates bureaucratic delays that restrict formulary access for rare or complex drugs, forcing providers to seek costly prior authorizations or alternative coverage pathways.
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
The distinction rests on whether executive session use remains narrowly tailored to legitimate commercial confidentiality versus expanding into routine procurement decisions that should remain publicly documented.
Sources · Amendment -MR5 — proposed amendment
Centralizing drug purchasing authority and leveraging supplemental rebates may lower state costs and stabilize recipient premiums, but it concentrates procurement power in OHA and a new advisory body, potentially reducing market competition and limiting direct formulary control for CCOs and providers.
Potential for significant state cost savings through bulk negotiation and multistate pooling
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Standardized drug pricing across medical assistance programs may reduce administrative complexity
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Mandated annual reporting increases transparency on rebate collections and savings
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Concentrated procurement power may reduce manufacturer competition or innovation incentives
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
CCOs lose direct formulary control, potentially creating access delays for specialized medications
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Executive session provisions limit public oversight of confidential contract terms
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
high confidence. Analysis is strictly grounded in the supplied proposed amendment text and official committee/fiscal documents. All claims are bounded by statutory language and explicitly labeled as inferences where applicable.
The amendment replaces SB 1528's study requirement with technical amendments to existing Oregon Laws 2023. It delays the operative date of ORS 441.765 by one year (to July 1, 2027), sets the operative date of ORS 653.258 and related wage/hour provisions to June 1, 2025, and authorizes the Bureau of Labor and Industries Commissioner to take necessary actions before that date.
Basis: Stakeholder claim · Source: Amendment -3 — proposed amendment
Official sources do not state why this measure was proposed.
Sponsor testimony, staff summaries, committee materials, or statutory findings may explain it.
Inferred from cited text; not a stated purpose.
The amendment likely corrects a statutory implementation gap or misalignment by extending the timeline for health care regulatory duties while establishing a definitive start date for labor provisions and allowing early administrative preparation.
Basis: Inferred · Source: Amendment -3 — proposed amendment
OHA's authority under ORS 441.765 is delayed until July 1, 2027, preventing the exercise of statutory duties during the intervening period.
Basis: Inferred · Source: Amendment -3 — proposed amendment
BOLI gains authority to take pre-implementation actions before June 1, 2025, and assumes full duties under ORS 653.258 and amendments to ORS 653.261 on that date.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Compliance, licensing, or regulatory requirements tied to this statute are postponed until July 1, 2027.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Provisions become operative on June 1, 2025; BOLI may enforce or regulate related matters before this date if deemed necessary.
Basis: Inferred · Source: Amendment -3 — proposed amendment
OHA must defer all implementation activities for ORS 441.765 until July 1, 2027, potentially affecting budgeting, staffing, and regulatory timelines.
Basis: Inferred · Source: Amendment -3 — proposed amendment
BOLI can initiate preparatory work for ORS 653.258 immediately or before June 1, 2025, without waiting for the operative date.
Basis: Inferred · Source: Amendment -3 — proposed amendment
The amendment has minimal fiscal impact on state or local government expenditures and no revenue impact.
Basis: Stakeholder claim · Sources: Fiscal Impact Statement A; Revenue Impact Statement A
BOLI and labor market participants
BOLI uses pre-implementation authority to establish critical wage enforcement mechanisms or guidance before June 1, 2025, preventing a gap in worker protections and ensuring immediate compliance readiness.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Health care consumers and regulated entities
The one-year delay for ORS 441.765 postpones essential health care regulatory oversight or licensing requirements, leaving a regulatory vacuum or delaying consumer protections until July 2027.
Basis: Inferred · Source: Amendment -3 — proposed amendment
The text grants broad pre-implementation authority without defining limits on enforcement versus preparation.
Sources · Amendment -3 — proposed amendment
The measure trades an additional year of delay for health care regulatory implementation under ORS 441.765 against early administrative preparation and a confirmed June 2025 start for labor provisions under ORS 653.258.
Allows BOLI to prepare effectively for labor provisions, reducing implementation risk.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Confirms a definitive operative date for ORS 653.258, providing certainty for employers and employees.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Postpones health care statutory duties by one year, potentially delaying intended consumer protections or oversight.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Broad pre-implementation authority for BOLI may create uncertainty regarding the scope of permissible actions before June 1, 2025.
Basis: Inferred · Source: Amendment -3 — proposed amendment
high confidence. The amendment text is explicit regarding operative dates and statutory references. Supporting sources confirm fiscal neutrality but contain unrelated content regarding drug reporting, which does not affect the analysis of the amendment's text.
The amendment would expand Oregon’s prescription drug price transparency program to require manufacturers to annually report detailed pricing, cost, revenue, and profit data for drugs with significant price increases, plus comprehensive reporting on all patient assistance programs serving Oregon consumers. It establishes a public disclosure framework with trade secret protections, creates civil penalties for noncompliance, and mandates an annual legislative report with recommendations to control drug costs.
Basis: Inferred · Source: Amendment -2 — proposed amendment
The measure responds to a 2025 legislative report recommendation requiring manufacturers to report annually on all patient assistance programs they maintain or fund.
Basis: Official analysis · Source: Staff Measure Summary A
Inferred from cited text; not a stated purpose.
Expanding reporting to cover all patient assistance programs regardless of price triggers suggests an intent to close transparency gaps where discount programs might obscure net prices or limit the apparent impact of price increases on consumers.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Must collect, verify, and submit extensive financial, pricing, and program data annually or upon new drug introduction; face civil penalties for noncompliance.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Gains administrative authority to receive reports, manage trade secret exemptions, post data publicly, request additional information, and compile annual legislative recommendations.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Gain access to aggregated pricing and assistance program data via public channels; can confidentially report price increases to the department.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Receive direct access to manufacturer financial data to inform policy or purchasing decisions.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Manufacturers will incur compliance costs for data aggregation, auditing, and reporting infrastructure aligned with department rules.
Basis: Inferred · Source: Amendment -2 — proposed amendment
The department will require administrative capacity to process reports, manage public posting, handle trade secret claims, and enforce penalties.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Consumers and policymakers will have standardized visibility into net drug costs after manufacturer discounts, potentially influencing purchasing decisions or insurance formulary placements.
Basis: Inferred · Source: Amendment -2 — proposed amendment
While the measure incorporates federal definitions for pricing thresholds and drug classifications, the reporting obligations, enforcement mechanisms, and public disclosure rules remain strictly governed by Oregon state law.
Basis: Inferred · Source: Amendment -2 — proposed amendment
The January 1, 2028 operative date allows manufacturers time to adjust reporting systems before enforcement begins.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Low-income Oregon consumers and state purchasing entities
A manufacturer with a high-cost specialty drug uses aggressive patient assistance programs that effectively reduce out-of-pocket costs to near zero for low-income patients; comprehensive reporting reveals the true gross price and discount volume, enabling policymakers to negotiate bulk purchasing or cap out-of-pocket expenses based on verified assistance data.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Small biotech or specialty drug manufacturers
A small firm faces prohibitive compliance costs to itemize public-funded research and development, direct marketing expenses, and international pricing for a niche drug with minimal Oregon sales; the threat of civil penalties for minor reporting discrepancies forces the firm to withdraw from the Oregon market or raise prices to offset administrative burdens.
Basis: Inferred · Source: Amendment -2 — proposed amendment
The text legally permits manufacturers to claim trade secret exemptions under state law for submitted financial data. A potential unlawful outcome could arise if manufacturers systematically overclaim exemptions to shield competitive pricing strategies, relying on weak department review or delayed attorney general petition processes to maintain opacity. Conversely, the department could misclassify legitimate public interest disclosures as exempt, chilling transparency.
Sources · Amendment -2 — proposed amendment
The measure trades increased manufacturer compliance burdens and potential market withdrawal for niche drugs against greater consumer and policymaker visibility into net drug costs and discount program usage. Upsides include informed purchasing decisions and targeted cost-containment policies; downsides include administrative costs, possible reduced access to specialized medications, and reliance on effective enforcement of trade secret protections.
Standardized visibility into net drug costs after manufacturer discounts, potentially influencing purchasing decisions or insurance formulary placements.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Targeted cost-containment policies based on verified assistance program data and legislative recommendations.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Administrative costs for manufacturers and the department to process reports, manage public posting, handle trade secret claims, and enforce penalties.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Possible reduced access to specialized medications if small firms withdraw from the Oregon market or raise prices to offset compliance burdens.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Reliance on effective enforcement of trade secret protections to prevent opacity or chilling of transparency.
Basis: Inferred · Source: Amendment -2 — proposed amendment
high confidence. The amendment text is explicit regarding reporting triggers, data requirements, enforcement mechanisms, and operative dates. Official fiscal and staff analyses confirm minimal revenue impact and clarify the legislative recommendation driving the change.
The amendment would require prescription drug manufacturers selling in Oregon to annually report comprehensive data on all patient assistance programs (PAPs) serving state residents, regardless of whether a drug’s price increased. It expands existing transparency mandates, establishes civil penalties for noncompliance, requires the Department of Consumer and Business Services (DCBS) to publicly post most submitted data (subject to trade secret exemptions), and directs an annual legislative report with cost-containment recommendations.
Basis: Inferred · Source: Amendment -2 — proposed amendment
The measure responds to a 2025 recommendation from Oregon’s Prescription Drug Price Transparency program to require manufacturers to report annually on all PAPs they maintain or fund.
Basis: Official analysis · Source: Staff Measure Summary A
Inferred from cited text; not a stated purpose.
Lawmakers may be seeking to evaluate whether PAPs are effectively reducing consumer out-of-pocket costs or inadvertently masking underlying price increases, given the amendment’s focus on tracking program duration, eligibility verification, and total assistance value.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Must collect and submit granular PAP data annually by March 15, alongside existing price-increase and new-drug reporting obligations.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Bears administrative responsibility for verifying reports, managing public posting, adjudicating trade secret claims, and compiling annual legislative recommendations.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Gain access to standardized data on PAP eligibility, duration, and total assistance value, potentially improving program navigation and advocacy leverage.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Receive consolidated annual data and policy recommendations to inform future drug cost legislation.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Manufacturers will need internal compliance systems to track PAP participation, eligibility criteria, and financial assistance values across all Oregon patients.
Basis: Inferred · Source: Amendment -2 — proposed amendment
DCBS must develop verification protocols, a public data portal, and a process for handling trade secret petitions and Attorney General reviews.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Civil penalties under ORS 646A.692 apply to late, missing, or inaccurate submissions.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Public posting of PAP metrics may alter manufacturer program design or eligibility thresholds to avoid competitive scrutiny.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Oregon consumers and patients
Public disclosure reveals that a major manufacturer’s PAP excludes patients above 200% of the federal poverty level despite marketing claims of broad access; legislative committees use the data to mandate standardized eligibility tiers, reducing patient financial toxicity statewide.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Prescription drug manufacturers selling in Oregon
A manufacturer faces escalating civil penalties and protracted litigation over trade secret exemptions for proprietary pricing algorithms, ultimately withdrawing a specialty drug from the Oregon market or drastically curtailing PAP funding due to compliance costs and competitive exposure.
Basis: Inferred · Source: Amendment -2 — proposed amendment
The statutory exemption hinges on a public-interest balancing test that lacks objective thresholds, creating room for broad confidentiality claims to shield competitive pricing methodologies.
Sources · Amendment -2 — proposed amendment
Expanding PAP transparency increases market visibility and consumer protection but imposes significant administrative costs on manufacturers and state agencies while risking competitive harm through forced disclosure of proprietary program structures.
Standardized patient assistance access and data-driven cost-containment policy.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Enhanced legislative oversight of drug pricing and manufacturer discount practices.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Compliance burdens and potential trade secret litigation for manufacturers.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Possible manufacturer withdrawal or program restructuring to limit public exposure.
Basis: Inferred · Source: Amendment -2 — proposed amendment
high confidence. The amendment text is explicit regarding reporting triggers, required data fields, enforcement mechanisms, and public posting rules. Official fiscal and revenue impact statements confirm minimal state expenditure. Remaining uncertainty centers on implementation rules and industry response.
The proposed amendment replaces the original bill text with provisions that delay the operative date of prescription drug price transparency rules by one year to July 1, 2027, and sets the operative date for specific labor commissioner powers to June 1, 2025 while authorizing pre-emptive administrative preparation.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Official sources do not state why this measure was proposed.
Sponsor testimony, staff summaries, committee materials, or statutory findings may explain it.
Inferred from cited text; not a stated purpose.
The amendment may reflect a legislative adjustment to extend compliance timelines for drug manufacturers while correcting or validating the effective date of labor provisions, as indicated by the shift to a past operative date and the addition of preparatory authority for the Bureau of Labor and Industries.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Delayed compliance with ORS 441.765 provisions by one year, extending the timeline for implementing reporting or transparency requirements.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Postponed access to drug pricing transparency data mandated by the delayed provisions, potentially affecting cost awareness and market competition.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Granted authority to take preparatory actions before the June 1, 2025 operative date for ORS 653.258 and related amendments; subject to a past operative date that may require validation of prior administrative steps.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Adjusted timelines for implementing drug-related provisions, with no revenue impact noted.
Basis: Inferred · Sources: Amendment -3 — proposed amendment; Fiscal Impact Statement A
Manufacturers gain an additional year to align systems or policies with ORS 441.765 requirements, reducing immediate administrative burdens.
Basis: Inferred · Source: Amendment -3 — proposed amendment
BOLI can initiate rulemaking or administrative preparations immediately, ensuring readiness for the June 1, 2025 date, though the past operative date may necessitate retroactive validation of actions.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Fiscal impact is minimal per Legislative Revenue Office and Legislative Fiscal Office analyses, with no state or local revenue impact.
Basis: Stakeholder claim · Sources: IS_Impact SB 1528 2; Fiscal Impact Statement A
Drug manufacturers
A manufacturer avoids significant compliance costs by deferring implementation for a year, preserving capital during a period of market volatility or supply chain disruption.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Oregon consumers and workers
Consumers face prolonged exposure to opaque pricing structures due to the one-year delay, while BOLI's authority to act before the past operative date creates legal ambiguity that could be exploited to enforce unapproved policies or fail to address wage violations retroactively.
Basis: Inferred · Source: Amendment -3 — proposed amendment
The text permits preparatory actions but does not authorize enforcement of substantive duties before the operative date; misuse would constitute duty creep beyond the scope of the amendment.
Sources · Amendment -3 — proposed amendment
Delaying drug transparency requirements reduces immediate compliance burdens for manufacturers but postpones consumer access to pricing data that supports market competition and cost containment.
Extended timeline allows manufacturers more time to implement complex reporting systems, potentially reducing errors and administrative costs.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Preparatory authority for BOLI ensures that labor provisions can be implemented smoothly when the operative date arrives.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Consumers and policymakers lose a year of drug pricing data, which may hinder efforts to contain costs and inform healthcare decisions.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Setting an operative date in the past may create legal uncertainty regarding when duties attach and how prior administrative actions are validated.
Basis: Inferred · Source: Amendment -3 — proposed amendment
medium confidence. The analysis is based on the proposed amendment text and supporting documents. The amendment replaces the original measure, but the full context of what was replaced is not fully detailed in the provided sources. The past operative date for labor provisions introduces legal complexity that requires further clarification.
27 records currently loaded
Records available in the current snapshot.
Earliest loaded signal
Introduced bill text posted
Posted Jan 28, 2026, 3:25 PM PST
Follow the official text for SB 1528 and every amendment branch. Connections come from each amendment's stated base. Horizontal position shows when each document was first posted, when available.
Click a card to isolate its connected lines; use View summary to jump to its details. Horizontal position shows first posting time in Pacific Time. Drag or use the arrow keys to pan. Pinch with two fingers on mobile, or zoom with the controls, +/− keys, or Control/Command + scroll; press 0 to reset. Dashed branches remained proposals.
Selected document summary
Substantial replacement
What the document says to change
Delete lines 4 through 8 and insert:
Oregon records no individual sponsors.
Presession filing record
Printed pursuant to Senate Interim Rule 213.28 by order of the President of the Senate in conformance with presession filing rules, indicating neither advocacy nor opposition on the part of the President.
LC 101 became SB 1528
Mapping document posted: January 6, 2026 at 2:16 PM PST
Work Session — <b>Introduction of Committee Legislative Concepts</b> <i>When available, LC drafts will be posted on the committee’s OLIS page.</i> LC 100 LC 101 LC 102
Senate Interim Committee on Health Care introduction work session
Committee meeting: January 13, 2026 at 2:30 PM PST
HR C
Committee introduction motion
Committee meeting: January 13, 2026 at 2:30 PM PST
A motion was made to adopt the listed legislative concepts as committee bills.
Official vote: 5-0-0
Committee introduction allows consideration; it does not imply every member supported the introduced or final text.
The text changed substantially while keeping measure number SB 1528.
Senate carrier
Senator Deb Patterson
Third Reading Of Senate Measures · Version A
A carrier presents the measure or report but is not necessarily its sponsor or author.
Records already listed in Activity are not repeated here.
No meaningful relationship to Yex Labs LLC was found in the supplied artifact.
74% confidence · deterministic fallback
27 events
Full timeline
27 entries shown.
In committee upon adjournment.
Public Hearing held.
Public Hearing
Heard · Agenda item 4 · Room HR D · Expands drug manufacturer annual reporting requirements to include all patient assistance programs offered or funded by the manufacturer that provided assistance to consumers in this state in the previous calendar year.
Referred to Rules.
First reading. Referred to Speaker's desk.
Third reading. Carried by Patterson. Passed.
Ayes, 17; Nays, 10--Anderson, Girod, Hayden, McLane, Meek, Nash, Robinson, Starr, Thatcher, Weber; Excused, 3--Drazan, Linthicum, Smith DB.
Second reading.
Senate Amendments to Introduced bill text posted
Recommendation: Do pass with amendments. (Printed A-Eng.)
Work Session held.
Work Session
Heard and Reported Out with Amendments · Agenda item 3 · Room HR D · CARRIED OVER FROM THE 02/11/2026 MEETING: Requires the Oregon Health Authority to study health care.
Amendment -MR5 minority report
IS_Impact SB 1528 2
Revenue Impact Statement
Amendment -3 proposed
Amendment -2 adopted
Public Hearing held.
Public Hearing
Heard · Agenda item 3 · Room HR D · Requires the Oregon Health Authority to study health care.
IS_Impact SB 1528 2
Revenue Impact Statement
Amendment -2 proposed
Amendment -3 proposed
Referred to Health Care.
Introduction and first reading. Referred to President's desk.
n’s Prescription Drug Price Transparency program was established within DCBS by House Bill 4005 (2019). The program is required to report to the legislature by December 15 eac
“Expands drug manufacturer annual reporting requirements to include all patient assistance programs offered or funded by the manufacturer that provided assistance to consumers in this state in the previous calendar year.”
Confirm with the official record.
Supplemental, source-linked analysis from project researchers and community contributors. It is separate from Oregon's official record.